Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of enpatoran for active cutaneous lupus manifestations
2025-524855-30-00Phase 3Authorised
- Sponsor
- Merck KGaA
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) comparing Enpatoran plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: CLASI-70 response at Week 24. Planned start Aug 2026; status: authorised.
02
Drugs
enpatoran
03
Conditions
cutaneous lupus erythematosus (CLE)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2025-524855-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524855-30-00.